Till Örebro universitet

oru.seÖrebro universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010
Division of Obstetrics and Gynaecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden; Department of Obstetrics and Gynaecology in Linköping, County Council of Östergötland, Linköping, Sweden.
Division of Obstetrics and Gynaecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden; Department of Obstetrics and Gynaecology in Linköping, County Council of Östergötland, Linköping, Sweden; Local Health Care Research and Development Unit, County Council in Östergötland, Linköping, Sweden.
Local Health Care Research and Development Unit, County Council in Östergötland, Linköping, Sweden; Department of Medical and Health Sciences, Primary Care, Linköping University, Linköping, Sweden.
Local Health Care Research and Development Unit, County Council in Östergötland, Linköping, Sweden; Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden .
Visa övriga samt affilieringar
2013 (Engelska)Ingår i: BMJ Open, E-ISSN 2044-6055, Vol. 3, nr 10, artikel-id e003401Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: To investigate if continuation rates in first-time users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives.

Design: A longitudinal national population-based registry study.

Setting: The Swedish prescribed drug register.

Participants: All women born between 1977 and 1994 defined as first-time users of hormonal contraceptives from 2007 to 2009 (n=226211).

Main outcome measures: A tendency to switch the type of hormonal contraceptive within 6months use and repeated dispensation identical to the first were estimated as percentages and relative risks (RRs). Physicians' and midwives' prescription patterns concerning the women's continuation rates of oral hormonal contraceptive type.

Results: In Sweden, there were 782375 women born between 1977 and 1994 at the time of the study. Of these, 226211 women were identified as first-time users of hormonal contraceptives. Ethinylestradiol+levonorgestrel, desogestrel-only and ethinylestradiol+drospirenone were the hormonal contraceptives most commonly dispensed to first-time users at rates of 43.3%, 24.4% and 11.1%, respectively. The overall rate of switching contraceptive types in the first 6months was 11.3%, which was highest for desogestrel-only (14.3%) and lowest for ethinylestradiol+drospirenone (6.6%). The switching rate for all three products was highest in the 16-year to 19-year age group. Having a repeated dispensation identical to the initial dispensation was highest for users of ethinylestradiol either combined with levonorgestrel or drospirenone, 81.4% and 81.2%, respectively, whereas this rate for the initial desogestrel-only users was 71.5%. The RR of switching of contraceptive type within the first 6months was 1.35 (95% CI 1.32 to 1.39) for desogestrel-only and 0.63 (0.59 to 0.66) for ethinylestradiol+drospirenone compared with ethinylestradiol+levonorgestrel as the reference category. There were no differences in the women's continuation rates depending on the prescriber categories.

Conclusions: Desogestrel-only users conferred the highest switcher rate to another hormonal contraceptive within a 6-month period. Users of ethinylestradiol+levonorgestrel were more prone to switch to another product within 6months than women using ethinylestradiol+drospirenone. These findings may be of clinical importance when tailoring hormonal contraceptives on an individual basis.

Ort, förlag, år, upplaga, sidor
BMJ Publishing Group Ltd, 2013. Vol. 3, nr 10, artikel-id e003401
Nyckelord [en]
public health
Nationell ämneskategori
Gynekologi, obstetrik och reproduktionsmedicin
Identifikatorer
URN: urn:nbn:se:oru:diva-107939DOI: 10.1136/bmjopen-2013-003401ISI: 000326882800028PubMedID: 24141970Scopus ID: 2-s2.0-84886681845OAI: oai:DiVA.org:oru-107939DiVA, id: diva2:1792449
Tillgänglig från: 2023-08-29 Skapad: 2023-08-29 Senast uppdaterad: 2025-02-11Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Brynhildsen, Jan

Sök vidare i DiVA

Av författaren/redaktören
Brynhildsen, Jan
I samma tidskrift
BMJ Open
Gynekologi, obstetrik och reproduktionsmedicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 28 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf